AMS

Business Context and Reporting Period

Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2020
Business Overview: ASHS provides radiation therapy equipment and services, primarily through Gamma Knife units, Proton Beam Radiation Therapy (PBRT), and Intensity Modulated Radiation Therapy (IGRT). The company operates 16 Gamma Knife units, 1 PBRT system, and 1 IGRT machine. It holds majority ownership in subsidiaries including GK Financing, LLC (GKF) and operates a facility in Lima, Peru.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $753,000 (14.2%) year-over-year.
  • Gamma Knife: Revenue dropped $519,000 to $2.89 million due to lower average reimbursement rates at retail sites, despite a slight increase in procedure volume (376 vs. 375).
  • IGRT: Revenue fell $268,000 to $0 as the contract expired in April 2020 and the system was wound down.
  • PBRT: Revenue increased $34,000 to $1.68 million driven by higher treatment volumes (1,676 fractions vs. 1,546).
• Profitability: The company reported a net loss of $135,000 attributable to ASHS compared to net income of $270,000 in the prior year. This was driven by lower revenues and increased selling and administrative expenses ($156,000 increase) related to legal fees and senior management transition.
• Cost Structure: Total costs of revenue decreased by $210,000, primarily due to a $247,000 reduction in depreciation and amortization as IGRT equipment became fully depreciated.
• Liquidity: Cash and cash equivalents increased by $1.24 million, supported by strong operating cash flow of $3.39 million.

Outlook, Risks, and Management Commentary

• COVID-19 Impact: Management notes that the pandemic has caused delays in Gamma Knife and PBRT treatments due to facility restrictions and patient deferrals. While the impact in Q1 2020 was not material, the company anticipates a greater impact in Q2 2020. Commercial efforts have also been disrupted.
• Contract Expirations: An existing Gamma Knife customer contract expired in April 2020; the site is operating month-to-month with an expected lease termination in mid-2020. The IGRT contract also expired in April 2020.
• Capital Commitments: The company has significant future commitments, including:
  • $34 million commitment for two MEVION S250i PBRT systems (with $2.25 million in non-refundable deposits).
  • $5.56 million for Gamma Knife upgrades and a LINAC system.
  • $7.725 million for a second LINAC system and service agreement signed in April 2020.
• Liquidity Position: Management believes cash on hand and operating cash flows are adequate to meet scheduled debt and lease obligations for the next 12 months. Total contractual obligations over the next 12 months are approximately $6.95 million.
• Regulatory Risk: The company is monitoring the proposed Radiation Oncology Alternative Payment Model (RO APM) by CMS, which could alter reimbursement methodologies, though the impact remains uncertain.

Investor Verification Checklist

• Revenue Recovery: Verify the extent of treatment delays caused by COVID-19 in Q2 2020 and the rescheduling rate of deferred procedures.
• Contract Renewals: Confirm the status of the Gamma Knife site operating on a month-to-month basis and the likelihood of renewal or replacement.
• Capital Expenditure Financing: Assess the company's ability to secure financing for the $34 million PBRT commitment and other equipment upgrades, given the economic uncertainty.
• Reimbursement Rates: Monitor CMS reimbursement rate changes for 2020 and the potential long-term impact of the RO APM proposal.
• Management Transition: Evaluate the progress in identifying a permanent successor to the former President and CEO, as noted in the risk factors.